BioCorRx Files Patent Application with USPTO for Naltrexone Implant

Anaheim, CA - (NewMediaWire) - September 22, 2021 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) for a biodegradable implant including naltrexone. Several of the claims in the application are intended to cover BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), being developed under BioCorRx Pharmaceuticals, Inc., the Company’s controlled R&D subsidiary.

BioCorRx has received clearance from the FDA to proceed to human trials for BICX104 and expects to initiate the first-in-human clinical trial of the drug candidate as soon as scheduling permits. The project has been funded in large part by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925 and is a result of BioCorRx’s application under RFA DA-19-002, Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional).

Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., stated, “We are pleased to submit this patent application with the USPTO. We have made great progress to advance BICX104 towards FDA approval including receiving approximately $3.5 million of non-dilutive NIDA grant funding and expanding our development and manufacturing agreement with Recro, our CDMO. Filing this patent application is another important step as we move BICX104 into the clinical stage and prepare to initiate the first-in-human clinical trial of BICX104.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit for more information on UnCraveRx®. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

The content presented in this release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.